CYTO-200 AIMS™ Program

N/A

Report date: 2024/08/14 10:48:56
NME

Base Information

Drug NameCYTO-200 AIMS™ Program
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Multiple SclerosisCrohn Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCytocom Inc
China Registration ClassN/A

Develop Information

Active CompaniesCytocom Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Multiple SclerosisCrohn Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A